查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386284

人類乳突病毒 (HPV) 疫苗市場報告：2030 年趨勢、預測和競爭分析

Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

人類乳突病毒 (HPV) 疫苗趨勢與預測

到 2030 年，全球人類乳突病毒 (HPV) 疫苗市場預計將達到 103 億美元，2024 年至 2030 年複合年成長率為 10.4%。該市場的主要促進因素是人們對人類乳突病毒(HPV)疫苗益處的認知不斷提高、HPV感染疾病上升以及政府不斷舉措促進人類乳突病毒(HPV)疫苗。全球人類乳突病毒（HPV）疫苗市場未來性廣闊，醫院、零售藥局、政府供應通路都有商機。

人類乳突病毒 (HPV) 疫苗市場洞察

Lucintel 預測，四價疫苗預計將在預測期內實現最高成長，因為四價疫苗因其安全性和有效性特徵而被廣泛用於 9 至 12 歲的女孩和男孩。

由於人類乳突病毒(HPV)疫苗採用率高以及政府配合措施推廣人類乳突病毒(HPV)疫苗接種，預計北美在預測期內將出現最高成長。

本報告回答了 11 個關鍵問題：

  • Q.1. 區隔市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個區隔市場將以更快的速度成長？為什麼？
  • Q.3.哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要課題和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而促使市場佔有率下降的威脅有多大？
  • Q.11.過去五年發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章執行摘要

第2章全球人類乳突病毒（HPV）疫苗市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與課題

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球人類乳突病毒（HPV）疫苗市場趨勢（2018-2023）與預測（2024-2030）
  • 全球人類乳突病毒 (HPV) 疫苗市場（依類型）
    • 四價
    • 九價
    • 二價
  • 依配銷通路的全球人類乳突病毒 (HPV) 疫苗市場
    • 醫院和零售藥房
    • 政府供應商
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球人類乳突病毒（HPV）疫苗市場區域分佈
  • 北美人類乳突病毒（HPV）疫苗市場
  • 歐洲人類乳突病毒（HPV）疫苗市場
  • 亞太地區人類乳突病毒（HPV）疫苗市場
  • 其他地區人類乳突病毒（HPV）疫苗市場

第5章競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球人類乳突病毒 (HPV) 疫苗市場成長機會（依類型）
    • 全球人類乳突病毒 (HPV) 疫苗市場成長機會（依配銷通路）
    • 全球人類乳突病毒（HPV）疫苗市場成長機會（依地區）
  • 全球人類乳突病毒（HPV）疫苗市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球人類乳突病毒（HPV）疫苗市場產能
    • 全球人類乳突病毒（HPV）疫苗市場的合併、收購與合資
    • 認證和許可

第7章主要企業概況

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis
簡介目錄

Human Papillomavirus (HPV) Vaccine Trends and Forecast

The future of the global human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

A more than 150-page report is developed to help in your business decisions.

Human Papillomavirus (HPV) Vaccine by Segment

The study includes a forecast for the global human papillomavirus (HPV) vaccine by type, distribution channel, and region.

Human Papillomavirus (HPV) Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Tetravalent
  • Nonavalent
  • Bivalent

Human Papillomavirus (HPV) Vaccine Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

Human Papillomavirus (HPV) Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Human Papillomavirus (HPV) Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies human papillomavirus (HPV) vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the human papillomavirus (HPV) vaccine companies profiled in this report include-

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute Of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Human Papillomavirus (HPV) Vaccine Market Insights

Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Features of the Global Human Papillomavirus (HPV) Vaccine Market

Market Size Estimates: Human papillomavirus (HPV) vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Human papillomavirus (HPV) vaccine market size by type, distribution channel, and region in terms of value ($B).

Regional Analysis: Human papillomavirus (HPV) vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, and regions for the human papillomavirus (HPV) vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human papillomavirus (HPV) vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the human papillomavirus (HPV) vaccine market size?

Answer: The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030.

Q.2 What is the growth forecast for human papillomavirus (HPV) vaccine market?

Answer: The global human papillomavirus (HPV) vaccine market is expected to grow with a CAGR of 10.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the human papillomavirus (HPV) vaccine market?

Answer: The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

Q4. What are the major segments for human papillomavirus (HPV) vaccine market?

Answer: The future of the human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key human papillomavirus (HPV) vaccine market companies?

Answer: Some of the key human papillomavirus (HPV) vaccine companies are as follows:

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute Of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Q6. Which human papillomavirus (HPV) vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

Q7. In human papillomavirus (HPV) vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the human papillomavirus (HPV) vaccine market by type (tetravalent, nonavalent, and bivalent), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Human Papillomavirus (HPV) Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Human Papillomavirus (HPV) Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 3.3.1: Tetravalent
    • 3.3.2: Nonavalent
    • 3.3.3: Bivalent
  • 3.4: Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 3.4.1: Hospital & Retail Pharmacies
    • 3.4.2: Government Suppliers
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 4.2: North American Human Papillomavirus (HPV) Vaccine Market
    • 4.2.2: North American Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.3: European Human Papillomavirus (HPV) Vaccine Market
    • 4.3.1: European Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.3.2: European Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.4: APAC Human Papillomavirus (HPV) Vaccine Market
    • 4.4.1: APAC Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.4.2: APAC Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.5: ROW Human Papillomavirus (HPV) Vaccine Market
    • 4.5.1: ROW Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.5.2: ROW Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Human Papillomavirus (HPV) Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Johnson & Johnson
  • 7.2: Xenetic Biosciences
  • 7.3: AstraZeneca
  • 7.4: Merck
  • 7.5: Serum Institute of India
  • 7.6: Inovio Pharmaceuticals
  • 7.7: Bharat Biotech
  • 7.8: Sanofi
  • 7.9: GlaxoSmithKline
  • 7.10: Novartis